AR061295A1 - Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida - Google Patents

Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida

Info

Publication number
AR061295A1
AR061295A1 ARP070102497A ARP070102497A AR061295A1 AR 061295 A1 AR061295 A1 AR 061295A1 AR P070102497 A ARP070102497 A AR P070102497A AR P070102497 A ARP070102497 A AR P070102497A AR 061295 A1 AR061295 A1 AR 061295A1
Authority
AR
Argentina
Prior art keywords
methyl
phenyl
ethyl
amino
propenamide
Prior art date
Application number
ARP070102497A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061295A1 publication Critical patent/AR061295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El compuesto es util como inhibidor de histona-desacetilasa, antiproliferativo. Reivindicacion 1: Un método para preparar una sal cristalina de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida, que comprende los pasos de: (a) disolver o suspender la base libre de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida en una cantidad de solvente apropiado; y (b) tratar la base libre de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3- il)etil]amino]metil]fenil]-2E-2-propenamida a una temperatura apropiada con un agente formador de sal, en donde el agente formador de sal se selecciona del grupo que consiste de proveedores de iones de clorhidrato, lactato, maleato, mesilato, tartarato, acetato, benzoato, citrato, fumarato, gentisato, malato, malonato, oxalato, fosfato, propionato, sulfato, succinato, sodio, potasio, calcio y zinc.
ARP070102497A 2006-06-12 2007-06-08 Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida AR061295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452906P 2006-06-12 2006-06-12
US85325906P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
AR061295A1 true AR061295A1 (es) 2008-08-20

Family

ID=38832680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102497A AR061295A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida

Country Status (24)

Country Link
US (1) US7989639B2 (es)
EP (1) EP2032532B8 (es)
JP (1) JP2009540007A (es)
KR (1) KR20090026282A (es)
AR (1) AR061295A1 (es)
AU (1) AU2007257882B2 (es)
BR (1) BRPI0713653A2 (es)
CA (1) CA2654230C (es)
CL (1) CL2007001690A1 (es)
EC (1) ECSP088957A (es)
GT (1) GT200800281A (es)
HK (1) HK1126495A1 (es)
IL (1) IL195344A (es)
JO (1) JO3099B1 (es)
MA (1) MA30564B1 (es)
MX (1) MX2008015899A (es)
MY (1) MY147013A (es)
NO (1) NO20090136L (es)
NZ (1) NZ572744A (es)
PE (1) PE20080365A1 (es)
RU (1) RU2008151724A (es)
TN (1) TNSN08508A1 (es)
TW (1) TWI385142B (es)
WO (1) WO2007146717A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015212B1 (ru) * 2006-06-12 2011-06-30 Новартис Аг Соли n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
MX2008015898A (es) * 2006-06-12 2009-01-12 Novartis Ag Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma.
US20100292291A1 (en) * 2007-01-10 2010-11-18 Thitiwan Buranachokpaisan Formulations of deacetylase inhibitors
JP5485138B2 (ja) * 2008-03-28 2014-05-07 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
KR101808792B1 (ko) * 2013-12-02 2017-12-13 수벤 라이프 사이언시스 리미티드 1-[(2-브로모페닐)술포닐]-5-메톡시-3-[(4-메틸-1-피페라지닐)메틸]-1h-인돌 디메실레이트 모노히드레이트의 대규모 생산 방법
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20230416255A1 (en) * 2022-06-27 2023-12-28 Abion Inc. Mesylate salts of triazolopyrazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH342565A (de) 1954-04-14 1959-11-30 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Äthern endocyclisch substituierter Carbinole oder ihren nicht quaternären Salzen
GB891413A (en) 1958-10-06 1962-03-14 Smith Kline French Lab Tris-(dialkylaminoalkyl) phosphates and a method for their preparation
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003016307A1 (en) * 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
DK1443967T3 (da) * 2001-11-06 2007-04-16 Novartis Ag Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
JP2007524643A (ja) * 2004-04-26 2007-08-30 テバ ファーマシューティカル インダストリーズ リミティド テガセロドとマレイン酸テガセロドの調製
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts

Also Published As

Publication number Publication date
CA2654230A1 (en) 2007-12-21
MX2008015899A (es) 2009-04-01
TNSN08508A1 (en) 2010-04-14
EP2032532A2 (en) 2009-03-11
US20090187029A1 (en) 2009-07-23
WO2007146717A3 (en) 2008-03-27
IL195344A (en) 2014-11-30
HK1126495A1 (en) 2009-09-04
AU2007257882B2 (en) 2011-09-08
MA30564B1 (fr) 2009-07-01
CL2007001690A1 (es) 2008-05-16
RU2008151724A (ru) 2010-07-20
WO2007146717A2 (en) 2007-12-21
NO20090136L (no) 2009-03-06
EP2032532B1 (en) 2015-04-22
TWI385142B (zh) 2013-02-11
US7989639B2 (en) 2011-08-02
JP2009540007A (ja) 2009-11-19
MY147013A (en) 2012-10-15
TW200808692A (en) 2008-02-16
GT200800281A (es) 2009-03-18
EP2032532B8 (en) 2015-07-01
PE20080365A1 (es) 2008-05-07
BRPI0713653A2 (pt) 2012-10-23
AU2007257882A1 (en) 2007-12-21
NZ572744A (en) 2011-05-27
IL195344A0 (en) 2009-08-03
KR20090026282A (ko) 2009-03-12
CA2654230C (en) 2012-09-11
ECSP088957A (es) 2009-01-30
JO3099B1 (ar) 2017-03-15

Similar Documents

Publication Publication Date Title
AR061295A1 (es) Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
CO5650228A2 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
PE20080937A1 (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil)amino]metil]fenil]-2e-2-propenamida
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20010489A1 (es) Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismo
ATE475415T1 (de) Neue salze des wirkstoffs rasagilin
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
CY1111697T1 (el) Νεες συνθεσεις οι οποιες περιεχουν ενωσεις κινολινης
PE20121030A1 (es) Composicion farmaceutica que contiene un derivados de quinolina
BRPI0510231A (pt) composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
AR077422A1 (es) Sales de inhibidores de plk
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
RU2017141446A (ru) Энантиомеры 2-гидроксипроизводных жирных кислот
PE20120217A1 (es) Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica
Atlas DopAmide: Novel, Water‐Soluble, Slow‐Release l‐dihydroxyphenylalanine (l‐DOPA) Precursor Moderates l‐DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons
BR112013017416A2 (pt) derivado de indola ou indazola ou sal do mesmo
EA200801960A1 (ru) Соли дулоксетина
DK119684D0 (da) Quinoloncarboxylsyrer og disses anvendelse som baktericider
RU2008103699A (ru) Кристаллические формы динатриевой соли n-(-5-хлорсалицило-)-8-аминокаприловой кислоты
TW200745318A (en) Antistatic agent and antistatic resin composition containing the same
JP2005513201A5 (es)
AR045515A1 (es) Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables
JP2005508350A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure